GlassScriptPhysician profile
Luis G Rangel
NPI 1487645149
$24,447.14
in general payments reported to CMS, 2019-2025
67 companies · $4,550 in 2025
The $4,550 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $402 · 2021: $1,547 · 2022: $2,509 · 2023: $3,887 · 2024: $11K · 2025: $4,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,829 · Long Term Medical Supply Or Device Loan: $1,583 · Education: $594 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,189.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,829.00 |
| Long Term Medical Supply Or Device Loan | $1,583.27 |
| Education | $593.78 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,621.71 | 2020-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $3,575.81 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $2,561.43 | 2019-2025 | Erleada, Darzalex, Imbruvica |
| Pfizer INC. | $1,564.69 | 2019-2025 | |
| Celgene Corporation | $1,134.76 | 2021-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $1,030.91 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Genzyme Corporation | $1,025.60 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $593.41 | 2023-2024 | Trelstar |
| Daiichi Sankyo INC. | $549.14 | 2024-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $543.82 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $420.48 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $398.62 | 2021-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $367.14 | 2023-2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $334.73 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Lilly USA, LLC | $286.01 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $252.21 | 2021-2025 | Xtandi, Xospata |
| Stemline Therapeutics INC. | $231.40 | 2023-2025 | Orserdu |
| Incyte Corporation | $211.81 | 2023 | Jakafi |
| Beigene USA, INC. | $207.78 | 2022-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $189.87 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Emd Serono, INC. | $187.60 | 2023-2025 | Bavencio |
| Eisai INC. | $182.11 | 2023-2025 | |
| Taiho Oncology, INC. | $180.27 | 2022-2025 | |
| Sobi, INC | $173.46 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $171.41 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $165.36 | 2022-2023 | Tukysa |
| Ethicon INC. | $154.69 | 2024 | Monarch Platform |
| Adaptive Biotechnologies Corporation | $135.10 | 2022-2024 | Clonoseq |
| Amgen INC. | $134.67 | 2021-2023 | Lumakras |
| Jazz Pharmaceuticals INC. | $129.44 | 2023-2025 | |
| Array Biopharma INC | $110.60 | 2021-2024 | Mektovi, Braftovi, Lorbrena |
| Karyopharm Therapeutics INC. | $93.53 | 2023-2025 | Xpovio |
| Geron Corporation | $90.08 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $89.48 | 2019-2023 | Xarelto |
| Deciphera Pharmaceuticals INC. | $87.73 | 2021-2024 | Qinlock |
| Adc Therapeutics America, INC. | $84.70 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.60 | 2025 | |
| Cti Biopharma Corp. | $83.93 | 2022-2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $82.88 | 2023-2025 | Monoferric |
| Beone Medicines USA, INC. | $81.80 | 2025 | Brukinsa |
| Kite Pharma, INC. | $79.25 | 2023-2024 | Yescarta |
| Blueprint Medicines Corporation | $66.85 | 2023-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.88 | 2024 | Gilotrif |
| Gilead Sciences, INC. | $57.47 | 2021-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $51.50 | 2022 | |
| Myovant Sciences INC. | $49.36 | 2022 | |
| Mirati Therapeutics, INC. | $44.95 | 2023-2024 | Krazati |
| Genentech USA, INC. | $42.60 | 2023-2025 | Phesgo, Perjeta, Tecentriq |
| Tolmar, INC. | $42.03 | 2023-2024 | |
| Tempus Ai, INC | $37.32 | 2024 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $35.87 | 2024 | Onivyde |
| Morphosys, US INC. | $24.80 | 2023 | Monjuvi |
| Exelixis INC. | $23.91 | 2024 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $23.10 | 2022 | |
| Epizyme, INC. | $22.50 | 2022 | |
| Springworks Therapeutics, INC. | $21.78 | 2025 | Ogsiveo |
| Tolmar Pharmaceuticals, INC. | $20.99 | 2022 | |
| Caris Mpi, INC. | $19.83 | 2025 | Mi Cancer Seek |
| Sun Pharmaceutical Industries INC. | $19.67 | 2024 | |
| G1 Therapeutics, INC. | $19.23 | 2023 | Cosela |
| Puma Biotechnology, INC. | $17.85 | 2024 | |
| Abbott Laboratories | $17.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.98 | 2024 | Truxima |
| Verastem, INC. | $12.21 | 2019 | |
| Myriad Genetic Laboratories, INC. | $11.85 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Rangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.